Lilly’s atopic dermatitis drug hits endpoints

27th August 2019 Uncategorised 0

Both the 4mg and 2mg dosages met the trials’ primary endpoint in BREEZE-AD1 and BREEZE-AD2.

More: Lilly’s atopic dermatitis drug hits endpoints
Source: News